Role of non-classical MHC class I molecules in cancer immunosuppression

Por Kochan, Grazyna, Escors, David, Breckpot, Karine, Guerrero-Setas, David
Publicado em 2013

Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therape...

Por Liechtenstein, Therese, Perez-Janices, Noemi, Blanco-Luquin, Idoia, Goyvaerts, Cleo, Schwarze, Julia, Dufait, Ines, Lanna, Alessio, Ridder, Mark De, Guerrero-Setas, David, Breckpot, Karine, Escors, David
Publicado no Oncoimmunology (2014)

Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?

Por Escors, David, Liechtenstein, Therese, Perez-Janices, Noemi, Schwarze, Julia, Dufait, Ines, Goyvaerts, Cleo, Lanna, Alessio, Arce, Frederick, Blanco-Luquin, Idoia, Kochan, Grazyna, Guerrero-Setas, David, Breckpot, Karine
Publicado em 2013

CDH22 hypermethylation is an independent prognostic biomarker in breast cancer

Por Martín-Sánchez, Esperanza, Mendaza, Saioa, Ulazia-Garmendia, Ane, Monreal-Santesteban, Iñaki, Córdoba, Alicia, Vicente-García, Francisco, Blanco-Luquin, Idoia, De La Cruz, Susana, Aramendia, Ana, Guerrero-Setas, David
Publicado no Clin Epigenetics (2017)

A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice

Por Liechtenstein, Therese, Perez-Janices, Noemi, Gato, Maria, Caliendo, Fabio, Kochan, Grazyna, Blanco-Luquin, Idoia, Van der Jeught, Kevin, Arce, Frederick, Guerrero-Setas, David, Fernandez-Irigoyen, Joaquin, Santamaria, Enrique, Breckpot, Karine, Escors, David
Publicado em 2014

A core of kinase-regulated interactomes defines the neoplastic MDSC lineage

Por Gato-Cañas, Maria, de Morentin, Xabier Martinez, Blanco-Luquin, Idoia, Fernandez-Irigoyen, Joaquin, Zudaire, Isabel, Liechtenstein, Therese, Arasanz, Hugo, Lozano, Teresa, Casares, Noelia, Chaikuad, Apirat, Knapp, Stefan, Guerrero-Setas, David, Escors, David, Kochan, Grazyna, Santamaría, Enrique
Publicado no Oncotarget (2015)

CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer

Por Martín-Sánchez, Esperanza, Mendaza, Saioa, Ulazia-Garmendia, Ane, Monreal-Santesteban, Iñaki, Blanco-Luquin, Idoia, Córdoba, Alicia, Vicente-García, Francisco, Pérez-Janices, Noemí, Escors, David, Megías, Diego, López-Serra, Paula, Esteller, Manel, Illarramendi, José Juan, Guerrero-Setas, David
Publicado no Oncotarget (2017)

EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas

Por Perez-Janices, Noemi, Blanco-Luquin, Idoia, Tuñón, Maria Teresa, Barba-Ramos, Edurne, Ibáñez, Berta, Zazpe-Cenoz, Idoya, Martinez-Aguillo, Maria Teresa, Hernandez, Berta, Martínez-Lopez, Enrique, Fernández, Agustin F., Mercado, Maria Roasario, Cabada, Teresa, Escors, David, Megias, Diego, Guerrero-Setas, David
Publicado no Oncotarget (2015)

Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis

Por Perez-Janices, Noemi, Blanco-Luquin, Idoia, Torrea, Natalia, Liechtenstein, Therese, Escors, David, Cordoba, Alicia, Vicente-Garcia, Francisco, Jauregui, Isabel, De La Cruz, Susana, Illarramendi, José Juan, Coca, Valle, Berdasco, Maria, Kochan, Grazyna, Ibañez, Berta, Lera, José Miguel, Guerrero-Setas, David
Publicado no Oncotarget (2015)